Synta Pharmaceuticals (SNTA) Announces Positive Interim Results From The ENCHANT-1 Trial Of Ganetespib In Metastatic Breast Cancer At The 9th European Breast Cancer Conference
3/20/2014 10:22:17 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the Company’s lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. The results are being presented today in an oral session at the 9th European Breast Cancer Conference (EBCC) in Glasgow, Scotland at 9:45 AM local time.
Help employers find you! Check out all the jobs and post your resume.
comments powered by